143 related articles for article (PubMed ID: 15799447)
1. [Anti-rheumatoid biologics and pharmacoeconomic evaluation].
Tsutani K; Igarashi A
Nihon Rinsho; 2005 Jan; 63 Suppl 1():711-8. PubMed ID: 15799447
[No Abstract] [Full Text] [Related]
2. Etanercept or infliximab: the patient's considerations.
Sherrick RC
Arch Intern Med; 2006 Jul; 166(13):1418; author reply 1418. PubMed ID: 16832010
[No Abstract] [Full Text] [Related]
3. Anti-tumour necrosis factor therapy in the West Midlands.
Bartram D; Sheeran T; Price T; Mulherin D
Rheumatology (Oxford); 2004 Mar; 43(3):400; author reply 400-1. PubMed ID: 14963219
[No Abstract] [Full Text] [Related]
4. Maintaining and optimising anti-TNF therapy.
Somerville M
Musculoskeletal Care; 2007 Dec; 5 Suppl 1():1-17. PubMed ID: 18050263
[No Abstract] [Full Text] [Related]
5. Cost-effectiveness analysis of rituximab treatment in patients in Germany with rheumatoid arthritis after etanercept-failure.
Merkesdal S; Kirchhoff T; Wolka D; Ladinek G; Kielhorn A; Rubbert-Roth A
Eur J Health Econ; 2010 Feb; 11(1):95-104. PubMed ID: 19967426
[TBL] [Abstract][Full Text] [Related]
6. The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation.
Jobanputra P; Barton P; Bryan S; Burls A
Health Technol Assess; 2002; 6(21):1-110. PubMed ID: 12387732
[No Abstract] [Full Text] [Related]
7. Physician treatment preferences in rheumatoid arthritis of differing disease severity and activity: the impact of cost on first-line therapy.
Erkan D; Yazici Y; Harrison MJ; Paget SA
Arthritis Rheum; 2002 Jun; 47(3):285-90. PubMed ID: 12115159
[TBL] [Abstract][Full Text] [Related]
8. Effective coverage and reimbursement strategies for etanercept and infliximab in the treatment of rheumatoid arthritis.
Sokol MC
Manag Care Interface; 2005 Apr; 18(4):32-7. PubMed ID: 15889761
[TBL] [Abstract][Full Text] [Related]
9. Assessing the value of rheumatoid arthritis treatment alternatives: the potential effect of tumor necrosis factor inhibitors.
Mizutani W
Manag Care Interface; 2003 Mar; 16(3):44-50, 55. PubMed ID: 12715413
[TBL] [Abstract][Full Text] [Related]
10. [Innovative therapeutic options for psoriatic arthritis: TNFalpha inhibitors].
Lehnen M; Goos M; Dissemond J
Dtsch Med Wochenschr; 2004 Mar; 129(12):634-8. PubMed ID: 15011134
[No Abstract] [Full Text] [Related]
11. Clinical image: hidden costs of anti-tumor necrosis factor alpha therapy.
Mulherin D; Sheeran TP
Arthritis Rheum; 2003 Mar; 48(3):868. PubMed ID: 12632461
[No Abstract] [Full Text] [Related]
12. The burden of rheumatoid arthritis and access to treatment: uptake of new therapies.
Jönsson B; Kobelt G; Smolen J
Eur J Health Econ; 2008 Jan; 8 Suppl 2():S61-86. PubMed ID: 18097697
[TBL] [Abstract][Full Text] [Related]
13. Biologic therapy for rheumatoid arthritis.
Klippel JH
N Engl J Med; 2000 Nov; 343(22):1640-1. PubMed ID: 11096174
[No Abstract] [Full Text] [Related]
14. Medicare coverage of tumor necrosis factor alpha inhibitors as an influence on physicians' prescribing behavior.
DeWitt EM; Glick HA; Albert DA; Joffe MM; Wolfe F
Arch Intern Med; 2006 Jan; 166(1):57-63. PubMed ID: 16401811
[TBL] [Abstract][Full Text] [Related]
15. [TNF antagonists in therapy of rheumatoid arthritis].
Oberpichler-Schwenk H
Med Monatsschr Pharm; 1999 Nov; 22(11):334-9. PubMed ID: 10596266
[No Abstract] [Full Text] [Related]
16. Estimated medication costs of primary TNFα antagonist failure in patients with rheumatoid arthritis.
Rose E; Lequerré T; Pouplin S; Daragon A; Le Loët X; Vittecoq O
Joint Bone Spine; 2012 Jul; 79(4):421-2. PubMed ID: 22512937
[No Abstract] [Full Text] [Related]
17. Compliance with biologic therapies for rheumatoid arthritis: do patient out-of-pocket payments matter?
Curkendall S; Patel V; Gleeson M; Campbell RS; Zagari M; Dubois R
Arthritis Rheum; 2008 Oct; 59(10):1519-26. PubMed ID: 18821651
[TBL] [Abstract][Full Text] [Related]
18. Severe refractory rheumatoid arthritis successfully treated with combination rituximab and anti-tumor necrosis factor-alpha-blocking agents.
Koumakis E; Wipff J; Avouac J; Kahan A; Allanore Y
J Rheumatol; 2009 Sep; 36(9):2125-6. PubMed ID: 19738227
[No Abstract] [Full Text] [Related]
19. The role of tumor necrosis factor inhibitors in patients with RA.
Trethewey P
JAAPA; 2002 Sep; 15(9):23-4, 27, 30 passim. PubMed ID: 12395668
[No Abstract] [Full Text] [Related]
20. Anticytokine therapy--a new era in the treatment of rheumatoid arthritis?
O'Dell JR
N Engl J Med; 1999 Jan; 340(4):310-2. PubMed ID: 9920958
[No Abstract] [Full Text] [Related]
[Next] [New Search]
